Trials / Unknown
UnknownNCT05113069
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 for Injection as Monotherapy in Patients With B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1912 | SHR-A1912, dose escalation and expansion. |
Timeline
- Start date
- 2021-12-22
- Primary completion
- 2024-03-31
- Completion
- 2025-03-30
- First posted
- 2021-11-09
- Last updated
- 2023-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05113069. Inclusion in this directory is not an endorsement.